Articles On Genetic Signatures (ASX:GSS)

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck By Rudi Filapek-Vandyck, Editor Analysts at Ord Minnett have updated...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Pro Medicus’ growth story is far from over. How should investors deal with the valua...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Painchek is eyeing a market of 1.7 million US aged-care beds for its pain-detection device Genetic Signatures sizes up a $400 million US market The latest thrills and spills at life sciences AGMs   PainChek (ASX:PCK) lodged a US Food &amp...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from James McDona...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today’s Reports: ((AIS)) – Aeris...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Now could be the time to pounce on one small cap ASX stock if your risk tolerance allows for it. That's the view of analysts at Bell Potter, which believe this speculative stock could have a "lucrative opportunity" in the United States. Whi...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

Molecular diagnostics company Genetic Signatures (ASX:GSS) has announced that the US FDA has cleared its EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated workflow for marketing and sale in the US.

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

It was a tough start to the week for the St Barbara Ltd (ASX: SBM) share price. The ASX gold stock was down as much as 21% to 22 cents before eventually closing the session at 23.5 cents. Why did this ASX gold stock crash? Investors were hi...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

By now, all Australians would be aware of the woes that high inflation has brought upon us. After virtually disappearing as an economic concern for a decade, the post-pandemic era saw inflation rear its ugly head once more. This could have...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.75% to 7,784.4 points. Four ASX shares that have failed to follow the market higher today a...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Stock market crashes can cause a lot of pain when they do occasionally occur. When a crash happens, there's widespread and indiscriminate selling by fearful investors. While living through a bear market is unsettling, it can also often...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle East eased The focus has now shifted from Middle East tensions to company earnings   The ASX put on a relief rally after its -3% loss last wee...

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported a greenlight from the TGA to sell its flu test devices on the market. At the same time, the Health Care sector is up +1.27% – suggestin...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Metals ((AX1)) - Accent Group ((AMA)) - AMA Group ((APA)) - APA Group ((LTM)) - Arcadium Lithium ((A1N)) - ARN Media ((ABB)) - Aussie Broadband ((ASB)) - Austa...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

World Overnight SPI Overnight 7046.00 – 24.00 – 0.34% S&P ASX 200 7038.20 – 38.30 – 0.54% S&P500 4273.53 – 63.91 – 1.47% Nasdaq Comp 13063.61 – 207.71 – 1.57% DJIA 33618.88 – 388.00 – 1.14% S&P500 VIX 18.94 + 2.04...

World Overnight SPI Overnight 7111.00 – 7.00 – 0.10% S&P ASX 200 7076.50 + 7.70 0.11% S&P500 4337.44 + 17.38 0.40% Nasdaq Comp 13271.32 + 59.51 0.45% DJIA 34006.88 + 43.04 0.13% S&P500 VIX 16.90 – 0.30 – 1.74% US...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

By Rudi Filapek-Vandyck, Editor FNArena Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, Shaw and Partners and UBS....

If you have a high tolerance for risk, then read on! That's because Bell Potter has just upgraded two ASX biotech shares to buy ratings this morning. Here's why the broker is feeling upbeat about these high-risk stocks: Genetic Signatures...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listedequities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArenahas now ad...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian molecular diagnostics company Genetic Signatures has submitted an application to the US FDA for regulatory clearance to market its EasyScreen Gastrointestinal Parasite Detection Kit.

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Genetic Signatures jumps on FDA 510(k) application Allegra says FDA has questions related to its 510(k) application Proteomics granted patent in Japan   Genetic Signatures jumps almost 20pc on FDA update There were a couple of FDA-related...

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country. In A...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

  Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.